|
Accueil > Actualité
AstraZeneca: Tagrisso effective as adjuvant treatment
(CercleFinance.com) - At the weekend AstraZeneca announced that it had achieved "unprecedented" survival results in the treatment of early-stage lung cancer with its Tagrisso tablet.
The biopharmaceutical group reported that 88% of patients with EGFR-mutated non-small cell lung cancer enrolled in its "Adaura" phase III clinical trial were still alive after five years. The company says that Tagrisso reduced the risk of death by 51% compared with placebo, both in the primary target population and in the study population as a whole. Copyright (c) 2023 CercleFinance.com. All rights reserved. |
23/05/2025 17:40
UbisoftBarclays détient moins de 5% du capital 23/05/2025 17:10 Legrandla société FIL détient plus de 5% du capital 23/05/2025 17:02 PublicisBlackRock détient plus de 5% des droits de votes 23/05/2025 16:50 AlstomBlackRock sous les 5% du capital & des votes 23/05/2025 16:00 J&Jprésentera 70 résumés lors du congrès de l'ASCO 23/05/2025 15:52 Generalien recul avec une dégradation d'analyste Tous les articles sociétés |
